Peptides explained in plain language
Not medical advice
FDA-approvedCompounded · Rx

Compounded semaglutide after the shortage: what changed

The shortage that opened the door to compounded copies is over, and the rules for pharmacies have tightened.

Key takeaways

  • FDA declared the semaglutide shortage resolved on February 21, 2025, and the tirzepatide shortage resolved in December 2024.
  • With the shortages over, compounding pharmacies are much more limited in making copies of these drugs.
  • Compounded drugs are not FDA-approved and do not go through FDA review for safety, effectiveness or quality.
  • If you use a compounded GLP-1 now, ask your prescriber and pharmacist how it fits the current rules.

During the GLP-1 shortage, many people got semaglutide from compounding pharmacies instead of as Ozempic or Wegovy. That was possible because of a special rule for drugs in short supply. The shortage is now over, and that changes things. Here is what is different and what to ask if you are using, or thinking about, a compounded version.

Why compounded copies were allowed

Compounding is when a pharmacy mixes a medicine for a specific patient. It has real uses, such as making a version without an ingredient someone is allergic to. Federal law generally does not let pharmacies make routine copies of an FDA-approved drug. One big exception is when the drug is on FDA’s shortage list.

Semaglutide and tirzepatide were both in shortage for a long time. That opened the door for compounded copies, and many telehealth programs offered them.

What changed when the shortage ended

FDA declared the tirzepatide shortage resolved on December 19, 2024. It declared the semaglutide shortage resolved on February 21, 2025. FDA gave compounders a short grace period to wind down, and those grace periods have ended.

Now the normal rules apply again. In plain terms:

  • Pharmacies (503A): They can compound for individual patients with a prescription, but they cannot regularly make copies of an approved drug. A prescriber can document that a patient needs a meaningful change, such as leaving out an ingredient they react to. That’s different from a copy.
  • Outsourcing facilities (503B): These larger operations face tighter limits on using bulk semaglutide or tirzepatide now that the drugs are no longer in shortage.

FDA also issued an import alert in 2025 aimed at GLP-1 ingredients from unverified foreign sources. That makes it harder for questionable raw material to enter the country.

Approved does not mean the same as compounded. FDA reviews approved drugs for safety, effectiveness and quality. Compounded drugs skip that review, even when they contain the same named ingredient.
Get the weekly peptide brief

What changed in the rules, what new research says, and which claims to ignore. One email a week.

What FDA has seen with compounded GLP-1s

FDA has shared concerns about unapproved GLP-1 products. These include dosing mistakes when people measure their own doses, products that were not kept cold during shipping, and labels that make false claims. Some products have listed pharmacies that do not exist. FDA has received adverse event reports linked to both compounded semaglutide and compounded tirzepatide.

Questions to ask if you use a compounded version

  • Is this pharmacy state-licensed, and where is it located?
  • Why is a compounded version right for me instead of an approved product?
  • How will my dose be measured, and who can I call with questions?
  • How should it be shipped and stored?
  • What should I do if my supply changes or stops?

If a program cannot answer these clearly, that is a reason to pause. Your pharmacist is a good, free resource here. Also ask your prescriber whether an approved option, including a pill form, could work for you.

The bottom line

The shortage was the main reason compounded semaglutide was so easy to find. That reason is gone. Compounded versions can still exist in narrow cases, but they are not FDA-approved. Talk with your prescriber and pharmacist before starting, switching or stopping any GLP-1.

This article is for general education and isn’t medical or legal advice. It was written with AI assistance and may contain errors, so check anything that matters against the sources above and with a qualified healthcare professional before starting, stopping or changing any treatment. Why we say this.

Chris Janowski
About the author

Chris Janowski, owner and editor in chief

Chris Janowski is the editor in chief of Peptide Consumer Center. He started the site to give people a plain-language, well-sourced place to learn what peptides are, how they’re regulated and what the evidence actually says. Articles are written with AI assistance and published under his name.

Peptide Consumer Center is owned by Chris Janowski, who also owns PureVitaX, an online store that sells peptides, including several covered on this site. We link to PureVitaX, and Chris benefits when you buy there. Disclosures.